{"id":39172,"date":"2022-06-07T03:15:39","date_gmt":"2022-06-06T17:15:39","guid":{"rendered":"https:\/\/www.tomgrimshaw.com\/tomsblog\/?p=39172"},"modified":"2022-06-07T03:15:39","modified_gmt":"2022-06-06T17:15:39","slug":"unprecedented-remarkable-cancer-study-leaves-every-patient-cancer-free","status":"publish","type":"post","link":"https:\/\/www.tomgrimshaw.com\/tomsblog\/?p=39172","title":{"rendered":"\u2018Unprecedented\u2019, \u2018Remarkable\u2019: Cancer Study Leaves Every Patient Cancer-Free"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-39173\" src=\"http:\/\/www.tomgrimshaw.com\/tomsblog\/wp-content\/uploads\/2022\/06\/Cancer_Cells-300x168.jpg\" alt=\"Cancer Cells\" width=\"300\" height=\"168\" srcset=\"https:\/\/www.tomgrimshaw.com\/tomsblog\/wp-content\/uploads\/2022\/06\/Cancer_Cells-300x168.jpg 300w, https:\/\/www.tomgrimshaw.com\/tomsblog\/wp-content\/uploads\/2022\/06\/Cancer_Cells-768x430.jpg 768w, https:\/\/www.tomgrimshaw.com\/tomsblog\/wp-content\/uploads\/2022\/06\/Cancer_Cells.jpg 987w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>Results from a small cancer trial that left every patient in remission is being praised as \u201cunprecedented\u201d and \u201cremarkable.\u201d<\/p>\n<p>A\u00a0<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2201445\">paper<\/a>\u00a0published on Sunday at The New England Journal of Medicine outlined a study of 18 rectal cancer patients who were given dostarlimab every three weeks for six months and ended up cancer-free, including the first patient who is now two years out from the trial.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">\u201cI believe this is the first time this has happened in the history of cancer,\u201d said Dr. Luis A. Diaz Jr. said, an author of the paper,\u00a0The New York Times\u00a0<a href=\"https:\/\/www.nytimes.com\/2022\/06\/05\/health\/rectal-cancer-checkpoint-inhibitor.html\">reported<\/a>.<\/p>\n<p>Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and another author of the paper, described \u201ca lot of happy tears\u201d at the end of the trial.<\/p>\n<p><a href=\"https:\/\/www.dailywire.com\/news\/unprecedented-remarkable-cancer-study-leaves-every-patient-cancer-free\">https:\/\/www.dailywire.com\/news\/unprecedented-remarkable-cancer-study-leaves-every-patient-cancer-free<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results from a small cancer trial that left every patient in remission is being praised as \u201cunprecedented\u201d and \u201cremarkable.\u201d A\u00a0paper\u00a0published on Sunday at The New England Journal of Medicine outlined a study of 18 rectal cancer patients who were given dostarlimab every three weeks for six months and ended up cancer-free, including the first patient &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.tomgrimshaw.com\/tomsblog\/?p=39172\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;\u2018Unprecedented\u2019, \u2018Remarkable\u2019: Cancer Study Leaves Every Patient Cancer-Free&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,6],"tags":[],"class_list":["post-39172","post","type-post","status-publish","format-standard","hentry","category-general-interest","category-health-tips"],"_links":{"self":[{"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=\/wp\/v2\/posts\/39172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39172"}],"version-history":[{"count":1,"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=\/wp\/v2\/posts\/39172\/revisions"}],"predecessor-version":[{"id":39174,"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=\/wp\/v2\/posts\/39172\/revisions\/39174"}],"wp:attachment":[{"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tomgrimshaw.com\/tomsblog\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}